The European Medicines Agency has published for public consultation the ICH M15 Guideline on general principles for model-informed drug development.
This guideline provides general recommendations for planning, model evaluation, and documentation of evidence derived from Model-Informed Drug Development (MIDD). It establishes a harmonised assessment framework (including associated terminology) for MIDD evidence. It applies to both current and emerging modeling and simulation (M&S) methods and applications. It focuses on assessment of MIDD evidence and provides recommendations for related regulatory interactions, reporting, and submission. This guideline is intended to facilitate a multidisciplinary understanding of MIDD and associated evidence generation.
Comments should be provided using this template and sent to ich@ema.europa.eu by 28 February 2025.
The EMA may collect and further process some personal data of stakeholders and interested parties who submit contributions to the consultations. For more information, see Specific privacy statement for public and targeted consultations.